Unleashing The Potential Of Precision Medicine In Hypertrophic Cardiomyopathy Therapeutics
The condition known as hypertrophic cardiomyopathy (HCM) causes the heart muscle to enlarge abnormally. The heart has to work harder and pump blood less effectively because of the thickening heart muscle. Due to the fact that many affected individuals exhibit few or no symptoms, this condition frequently stays untreated. However, patients with Hypertrophic Cardiomyopathy (HCM) Therapeutics occasionally have shortness of breath, chest pain, or issues with the heart's electrical system, which can cause dangerously irregular heartbeats (arrhythmias) or unexpected death. The treatments include beta-blockade and verapamil either alone or in combination, while verapamil's vasodilatory activity in some people may cause LVOTO-associated symptoms. Disopyramide may be administered to patients with symptoms that are resistant to treatment.
Read More @ http://cmiblogpost.weebly.com/article/hypertrophic-cardiomyopathy-hcm-therapeutics-decreases-heart-failure
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian